Nutriband Inc. (NTRBW) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Orlando, FL, 미국. 현재 CEO는 Gareth Sheridan.
NTRBW 을(를) 보유 IPO 날짜 2021-10-01, 3 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $13.1M.
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. The company has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. Nutriband Inc. was incorporated in 2016 and is headquartered in Orlando, Florida.
